Long-Term Data Confirm TH Benefit in Early HER2-Positive Breast Cancer

Video

This video highlights 7-year follow-up data from the APT trial, which studied adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer.

In this video, Sara M. Tolaney, MD, MPH, of the Dana-Farber Cancer Institute in Boston, discusses 7-year follow-up data of the APT trial, which studied adjuvant paclitaxel/trastuzumab (TH) in early-stage patients with node-negative, HER2-positive breast cancer.

Tolaney presented the study results (abstract 511) at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, held June 2–6 in Chicago.

Related Videos
Joshua K. Sabari, MD, and Alexander I. Spira, MD, PhD, experts on non-small cell lung cancer
Joshua K. Sabari, MD, and Alexander I. Spira, MD, PhD, experts on non-small cell lung cancer
Joshua K. Sabari, MD, and Alexander I. Spira, MD, PhD, experts on non-small cell lung cancer
Joshua K. Sabari, MD, and Alexander I. Spira, MD, PhD, experts on non-small cell lung cancer
Joshua K. Sabari, MD, and Alexander I. Spira, MD, PhD, experts on non-small cell lung cancer
Experts on NSCLC
Expert on RCC
Joshua K. Sabari, MD, and Alexander I. Spira, MD, PhD, experts on non-small cell lung cancer
Related Content